Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Tolebrutinib is an oral Bruton's tyrosine kinase inhibitor designed to target neuroinflammation in multiple sclerosis.
• Further research is needed to establish its efficacy and safety in relapsing multiple sclerosis (RMS).

Purpose of the Study:

• To evaluate the efficacy and safety of tolebrutinib compared to teriflunomide in patients with relapsing multiple sclerosis.
• To assess the impact of tolebrutinib on annualized relapse rate and disability progression.

Main Methods:

• Two Phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 and GEMINI 2) were conducted.
• Participants with RMS were randomized to receive either tolebrutinib (60 mg daily) or teriflunomide (14 mg daily) with matching placebos.
• The primary endpoint was the annualized relapse rate; a key secondary endpoint was confirmed disability worsening.

Main Results:

• Tolebrutinib was not superior to teriflunomide in reducing the annualized relapse rate in both trials.
• A pooled analysis showed a lower percentage of participants with confirmed disability worsening (8.3% vs. 11.3%) in the tolebrutinib group.
• Adverse event rates were similar, but minor bleeding events (petechiae, heavy menses) were more common with tolebrutinib.

Conclusions:

• Tolebrutinib did not demonstrate superiority over teriflunomide in reducing annualized relapse rates for patients with relapsing multiple sclerosis.
• While tolebrutinib showed a potential benefit in delaying disability worsening, increased bleeding risk requires consideration.